Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
CYTOKINETICS INC executive Andrew Callos reported a small, tax-related stock sale. On the vesting of restricted stock units, he sold 2,582 shares of common stock on March 9, 2026 at $60.72 per share to satisfy company tax withholding obligations, and now directly holds 47,858 shares.
Cytokinetics EVP Research & Development Fady Ibraham Malik reported a small tax-related share sale. He sold 2,907 shares of Common Stock on March 9, 2026 in an open-market transaction at $60.72 per share.
According to the footnote, this was a sell-to-cover transaction to satisfy company tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale. After the transaction, he directly holds 138,629 shares of Cytokinetics common stock.
Cytokinetics President & CEO Robert I. Blum reported a small share sale primarily to cover tax obligations. On 2026-03-09, he sold 7,931 shares of common stock at $60.72 per share, described as a sell-to-cover transaction for company tax withholding on vested RSUs.
After this transaction, Blum directly holds 391,673 common shares, indicating the sale represents a minor portion of his direct stake. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC executive Andrew Callos, EVP and Chief Commercial Officer, reported multiple stock option exercises and related share sales. On March 5, 2026, he exercised two non-qualified stock options covering 11,000 and 15,000 shares, converting them into common stock through derivative exercises.
He then completed two open-market sales of common stock totaling 26,000 shares, with 15,000 shares sold at $61.87 per share and 11,000 shares sold at $61.88 per share. After these transactions, he held 50,440 shares of common stock directly. The reported stock options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued employment.
Cytokinetics Inc director Lynne Parshall reported an open-market sale of common stock. On March 2, 2026, she sold 5,000 shares at an average price of $61.21 per share. After this transaction, she directly owns 17,933 shares of Cytokinetics common stock.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and related share sale. On March 2, 2026, he exercised an Incentive Stock Option for 886 shares, converting it into 886 shares of common stock at $37.63 per share. The same day, he then sold 886 shares of common stock at $61.62 per share in an open-market transaction. After these transactions, he held 50,440 shares of Cytokinetics common stock directly. The option grant referenced in the filing vests in equal monthly installments over four years from its grant date.
Cytokinetics (CYTK) describes its evolution into a fully integrated specialty biopharmaceutical company after global approvals of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the U.S., Europe and China. The drug, a cardiac myosin inhibitor, launched in the U.S. in early 2026, with European and China commercialization rolling out through partners.
The company’s Vision 2030 strategy targets two product approvals across three indications and at least 10 new molecular entities, centered on muscle biology. Late‑stage programs include omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for a subset of HFpEF, plus early neuromuscular candidate CK‑089.
Cytokinetics has monetized part of future MYQORZO, omecamtiv mecarbil and ulacamten sales through revenue‑interest agreements with Royalty Pharma, and details extensive global patent coverage for its lead assets, with key aficamten patents potentially extending into the late 2030s and early 2040s.
Cytokinetics reported fourth-quarter and full-year 2025 results as it transitions into a commercial-stage company with MYQORZO. Revenue reached $88.0 million for 2025, up from $18.5 million in 2024, driven by $52.4 million from a technology transfer to Bayer and $15.0 million of MYQORZO approval milestones under the Sanofi agreement.
The company ended 2025 with about $1.22 billion in cash, cash equivalents and investments, including $100 million drawn from a Royalty Pharma loan. R&D expenses were $416.0 million and G&A expenses $284.3 million, reflecting clinical advancement and commercial build-out. Net loss widened to $784.9 million, or $(6.54) per share.
MYQORZO (aficamten) was approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., China and Europe, with a U.S. launch underway and a Germany launch planned in Q2 2026. For 2026, the company guided to GAAP combined R&D and SG&A expenses of $830 million to $870 million.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting a significant ownership position in Cytokinetics, Inc. common stock as of 12/31/2025.
The firm reports beneficial ownership of 17,716,372 shares, representing 14.5% of the outstanding common stock. It has sole voting power over 17,330,683 shares and sole dispositive power over 17,700,030 shares, with no shared voting or dispositive power.
T. Rowe Price states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cytokinetics, and it expressly denies being the beneficial owner of the securities beyond what is required for reporting.